Our areas of partnering interest
Are you wondering whether your novel science or technology may be of interest to AstraZeneca?
Here is a summary of the key areas in which we are keen to explore collaboration opportunities.
-
Oncology
-
Cardiovascular, Renal and Metabolism
-
Respiratory & Immunology
-
Infection and Vaccines
-
Precision Medicine
-
Enabling technologies
Oncology
In oncology, our ambition is to push the boundaries of science to change the practice of medicine, transform the lives of patients living with cancer, and ultimately eliminate cancer as a cause of death. Our oncology activities are concentrated around four strategic imperatives.
- Focus research on four scientific platforms: Tumour Drivers and Resistance; Immuno-Oncology; DNA Damage Response, and Antibody Drug Conjugates
- Focus on early stages of disease and relapsed or refractory patients
- Lead precision medicine in the most prevalent and deadly tumour types
- Leverage our global footprint
Cardiovascular, Renal and Metabolism
In CVRM, our mission is to protect the lives of 50 million people in the next year from the often-devastating consequences of heart failure, cardiovascular, metabolic and renal diseases. Shared risk factors of CVRM diseases are still often not diagnosed or addressed, and we are committed to help change clinical practice, to address unmet medical needs and create a seamless disease management pathway for patients worldwide.
Respiratory & Immunology
AstraZeneca is an established leader in respiratory care. We aim to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death. With common pathways and underlying disease drivers across respiratory and immunology, we are following the science from chronic lung diseases to immunology-driven disease areas. Our growing presence in immunology is focused on five mid- to late-stage franchises with multi-disease potential, in areas including rheumatology (including Systemic Lupus Erythematosus), dermatology, gastroenterology, and systemic eosinophilic-driven diseases. Our ambition is to achieve disease modification and durable remission for millions of patients worldwide.
Infection and Vaccines
We work to protect patients against the burden of influenza, respiratory syncytial virus (RSV) and bacterial infections, particularly those resistant to current antibiotics. Working with the wider infection community, we aim to translate science into solutions to address the global challenges faced in these disease areas.
Precision Medicine
More than 90 percent of our pipeline now follows a precision medicine approach. We collaborate with a wide range of experts to identify, validate and develop diagnostics to regulatory standards globally, and to commercialise innovative biomarker capabilities for patient selection, disease identification, pharmacological assessment and drug response monitoring.
Enabling technologies
We are interested in cutting-edge technologies to enhance the quality, effectiveness and productivity of our research and translational capabilities.
Collaboration opportunities in China and other international markets
No matter where in the world you may be located, we are interested in exploring leading-edge collaboration opportunities with you – across our main therapy areas and beyond. We carefully consider local medical circumstances and adopt a flexible approach that enables us to meet specific patient needs in key markets.
In China, for example, we are exploring opportunities that support and enhance our existing commercial strength. Our focus is on partnering opportunities at or near commercial launch stage, in areas such as pediaetric, nebulised, pulmonary, gastric, cardiovascular, and traditional Chinese medicine. Our interest goes beyond pharmaceutical products to diagnostics, devices, and digital technologies. We aim to work with a range of partners to build end-to-end patient solutions that help improve disease awareness, diagnosis, treatment and post-treatment care. While these partnerships are designed to meet the unmet medical needs of local patients, some also have potential to benefit patients globally.
Using our presence and reach, we can also help you commercialise your product in China and other international markets.
Our remarkable progress and presence in China
#2
pharmaceutical company in China*
2nd biggest
national market for AstraZeneca
19,000+
employees throughout China
$4,880m
Product Sales in 2019
35%
Product Sales growth in 2019 (at CER)
*Measured by value in the hospital sector (by sales)
Veeva ID: Z4-27153
Date of Prep: Sept 2020